Download PDF
Horm Metab Res 2022; 54(07): 481-488
DOI: 10.1055/a-1872-0546
Original Article: Endocrine Research

Downregulation of lncRNA ASMTL-AS1 in Epithelial Ovarian Cancer Correlates with Worse Prognosis and Cancer Progression

Hui Xu‡
1   Department of Obstetrics and Gynecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
,
Yan Tang‡
1   Department of Obstetrics and Gynecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
,
Lu Liu
1   Department of Obstetrics and Gynecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
,
Jie Yan
1   Department of Obstetrics and Gynecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
,
Li Qin
1   Department of Obstetrics and Gynecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Given the characters of “Silent killer”, epithelial ovarian cancer (EOC) usually suffered late diagnosis and poor prognosis. Therefore, this study aimed to explore the prognostic significance of ASMTL-AS1 in EOC and investigated the effect of lncRNA ASMTL-AS1 dysregulation on tumor cellular function. ASMTL-AS1 expression was analyzed in 133 EOC tissues and five kinds of cell lines by RT-qPCR. The expression of ASMTL-AS1 was tested for correlation with clinical data using the chi-square test and clinical follow-up using Kaplan-Meier method with log-rank test. Further, the prognostic parameters in predicting EOC overall survival were assessed by using multivariate Cox proportional hazards analysis. In vitro assays, including MTT assay and transwell assay, were conducted using EOC cell lines with overexpression of ASMTL-AS1. In tumorous tissues and cell lines, ASMTL-AS1 was lowly expressed compared with normal ones. This downregulation was associated with the advanced FIGO stage, positive ascites cytology, and lymph node. In particular, low levels of ASMTL-AS1 were revealed to have a high prognostic impact on EOC. ASMTL-AS1 overexpression strongly decreased cell proliferation, migration, and invasion in vitro partly by moderating miR-1228-3p. This study demonstrates a significant role for lowly expressed ASMTL-AS1 in EOC allowing for the prediction of prognosis for EOC. Considering that ASMTL-AS1 is strongly involved in cell growth and invasion, ASMTL-AS1 may be a promising marker for EOC prognosis and therapy

Key words

LncRNA - ASMTL-AS1 - epithelial ovarian cancer - prognosis


Publication History

Received: 28 March 2022

Accepted after revision: 31 May 2022

Article published online:
14 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mattiuzzi C, Lippi G. Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur J Public Health 2020; 30: 1026-1027
    CrossrefPubMedGoogle Scholar
  • 2 Eloranta S, Smedby KE, Dickman PW. et al. Cancer survival statistics for patients and healthcare professionals – a tutorial of real-world data analysis. J Intern Med 2021; 289: 12-28
    CrossrefPubMedGoogle Scholar
  • 3 Neesham D, Richards A, McGauran M. Advances in epithelial ovarian cancer. Aust J Gen Pract 2020; 49: 665-669
    CrossrefPubMedGoogle Scholar
  • 4 Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. Am J Pathol 2021; 191: 26-39
    CrossrefPubMedGoogle Scholar
  • 5 Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 2016; 186: 733-747
    CrossrefPubMedGoogle Scholar
  • 6 Rojas V, Hirshfield KM, Ganesan S. et al. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and Treatment. Int J Mol Sci 2016; 17: 2113
    CrossrefPubMedGoogle Scholar
  • 7 Torre LA, Trabert B, DeSantis CE. et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68: 284-296
    CrossrefPubMedGoogle Scholar
  • 8 Peres LC, Sinha S, Townsend MK. et al. Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecol Oncol 2020; 156: 459-466
    CrossrefPubMedGoogle Scholar
  • 9 Gov E, Kori M, Arga KY. RNA-based ovarian cancer research from ‘a gene to systems biomedicine’ perspective. Syst Biol Reprod Med 2017; 63: 219-238
    CrossrefPubMedGoogle Scholar
  • 10 Wang JY, Lu AQ, Chen LJ. LncRNAs in ovarian cancer. Clin Chim Acta 2019; 490: 17-27
    CrossrefPubMedGoogle Scholar
  • 11 Braga EA, Fridman MV, Moscovtsev AA. et al. LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms. Int J Mol Sci 2020; 21: 8855
    CrossrefPubMedGoogle Scholar
  • 12 Fehringer G, Kraft P, Pharoah PD. et al. Cross-cancer genome-wide analysis of lung, ovary, breast, prostate, and colorectal cancer reveals novel pleiotropic associations. Cancer Res 2016; 76: 5103-5114
    CrossrefPubMedGoogle Scholar
  • 13 Xu C, Zhai J, Fu Y. LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis. Neoplasma 2020; 67: 782-793
    CrossrefPubMedGoogle Scholar
  • 14 Wang Y, Huang Y, Liu H. et al. Long noncoding RNA CDKN2B-AS1 interacts with miR-411-3p to regulate ovarian cancer in vitro and in vivo through HIF-1a/VEGF/P38 pathway. Biochem Biophys Res Commun 2019; 514: 44-50
    CrossrefPubMedGoogle Scholar
  • 15 Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-352
    CrossrefPubMedGoogle Scholar
  • 16 Sun J, Li X, Yu E. et al. A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer. Diagn Pathol 2021; 16: 45
    CrossrefPubMedGoogle Scholar
  • 17 Zheng J, Guo J, Zhang H. et al. Four prognosis-associated lncRNAs serve as biomarkers in ovarian cancer. Front Genet 2021; 12: 672674
    CrossrefPubMedGoogle Scholar
  • 18 Tan CH, Sim DSY, Lim SH. et al. Antiproliferative and microtubule-stabilizing activities of two iboga-vobasine bisindoles alkaloids from tabernaemontana corymbosa in colorectal adenocarcinoma HT-29 cells. Planta Med 2022; 31 DOI: 10.1055/a-1755-5605 Epub ahead of print.
    PubMedGoogle Scholar
  • 19 Li Y, Pan B, Guo X. et al. Prognostic value of long noncoding RNA SNHG11 in patients with prostate cancer. Horm Metab Res 2022; 54: 187-193
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Wang X, Chen W, Lao W. et al. Silencing LncRNA PVT1 reverses high glucose-induced regulation of the high expression of PVT1 in HRMECs by targeting miR-128-3p. Horm Metab Res 2022; 54: 119-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Yaghoobi H, Babaei E, Hussen BM. et al. EBST: An evolutionary multi-objective optimization based tool for discovering potential biomarkers in ovarian cancer. IEEE/ACM Trans Comput Biol Bioinform 2020; 18: 2384-2393
    CrossrefPubMedGoogle Scholar
  • 22 Nersesian S, Glazebrook H, Toulany J. et al. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol 2019; 10: 1782
    CrossrefPubMedGoogle Scholar
  • 23 Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol 2017; 28: viii61-viii65
    CrossrefPubMedGoogle Scholar
  • 24 Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 2017; 17: 577-591
    CrossrefPubMedGoogle Scholar
  • 25 Feng Z, Chen R, Huang N. et al. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma. Life Sci 2020; 244: 117298
    CrossrefPubMedGoogle Scholar
  • 26 Ma D, Gao X, Liu Z. et al. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif 2020; 53: e12795
    PubMedGoogle Scholar
  • 27 Luo Z, Xiao L, Li J. et al. Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. Medicine (Baltimore) 2019; 98: e14302
    CrossrefPubMedGoogle Scholar
  • 28 Qing L, Gu P, Liu M. et al. Extracellular matrix-related six-lncRNA signature as a novel prognostic biomarker for bladder cancer. Onco Targets Ther 2020; 13: 12521-12538
    CrossrefPubMedGoogle Scholar
  • 29 Zhu FF, Zheng FY, Wang HO. et al. Downregulation of lncRNA TUBA4B is associated with poor prognosis for epithelial ovarian cancer. Pathol Oncol Res 2018; 24: 419-425
    CrossrefPubMedGoogle Scholar
  • 30 Xue Z, Zhu X, Teng Y. Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. Mol Med Rep 2018; 18: 5173-5181
    PubMedGoogle Scholar
  • 31 Dai L, Niu J, Feng Y. Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin. J Cell Mol Med 2020; 24: 202-213
    CrossrefPubMedGoogle Scholar
  • 32 Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci 2018; 19: 1310
    CrossrefPubMedGoogle Scholar
  • 33 Russo F, Fiscon G, Conte F. et al. Interplay between long noncoding RNAs and microRNAs in cancer. Methods Mol Biol 2018; 1819: 75-92
    CrossrefPubMedGoogle Scholar
  • 34 Qi X, Zhang DH, Wu N. et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet 2015; 52: 710-718
    Google Scholar
  • 35 Li X, Lin S, Mo Z. et al. CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/p53/epithelial-mesenchymal transition (EMT) axis. J Cancer 2020; 11: 599-609
    CrossrefPubMedGoogle Scholar